

Discontinuation of oral antivirals in chronic hepatitis B ...

<https://pubmed.ncbi.nlm.nih.gov/27100145>

The possibility of safe discontinuation of therapy with nucleos (t)ide analogues (NAs) remains one of the most controversial topics in the management of chronic hepatitis B. Therefore, we systematically reviewed the existing data on NA discontinuation in this setting and tried to identify factors affecting the probability of posttherapy remission. A literature search was performed in order to identify all ...

Cited by: 157 Author: George Papatheodoridis, Ioannis Vlachog...

Publish Year: 2016

Outcome after discontinuing antiviral agents during ...

<https://www.ncbi.nlm.nih.gov/pubmed/23273664>

However, there are limited data on the outcome in pregnant women after withdrawal of antiviral agents.

OBJECTIVES: We aimed to investigate the outcome of stopping antiviral agents in pregnant women with chronic hepatitis B virus (HBV) infection. STUDY DESIGN: In this single-center, retrospective cohort study, 12 pregnant patients who had ...

Cited by: 19 Author: Hee Yeon Kim, Jong Young Choi, Chung...

Publish Year: 2013

Why not to stop antiviral treatment in patients with ...

<https://pubmed.ncbi.nlm.nih.gov/29427480>

At present, there is no consensus among the three major guidelines for the treatment of chronic hepatitis B on whether or not to stop antiviral treatment. One of the main reasons for this controversy is that virological relapse has been well documented in patients with chronic hepatitis B who stop treatment.

Relapse rate is particularly high in patients who are HBeAg-negative when treatment begins, with reported relapse rates of up to 70% 36 months ...

Cited by: 7 Author: Sebastián Marciano, Adrián Gadano

Publish Year: 2018

Antiviral response is not sustained after cessation of ...

<https://www.ncbi.nlm.nih.gov/pubmed/27769101>

Despite meeting the requirements for treatment discontinuation, approximately half of the CHB patients treated with lamivudine relapsed. Thus, the antiviral response is not reliably sustained after lamivudine treatment cessation. J. Med. Virol. 89:849-856, 2017. © 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc. PMID: 27769101

517,000 Results

Any time ▾

Why not to stop antiviral treatment in patients with ...<https://www.ncbi.nlm.nih.gov/pubmed/29427480>

Why not to stop antiviral treatment in patients with chronic hepatitis B. Marciano S(1), Gadeno A(1).
Author information: (1)Liver Unit and Department of Research, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Treatment of chronic hepatitis B with entecavir or tenofovir leads to viral suppression in almost all patients.

Cited by: 8

Publish Year: 2018

Author: Sebastián Marciano, Adrián Gadeno

Antiviral therapy of chronic hepatitis B: can we clear the ...<https://pubmed.ncbi.nlm.nih.gov/15646843>

Antiviral therapy of chronic HBV infection remains a clinical challenge. Once this infection has been established, the viral genome persists for life, either as an integrated genome or as episomal covalently closed circular DNA (cccDNA). The latter is the source of renewed viral replication in case ...

Cited by: 73

Publish Year: 2004

Author: Fabien Zoulim

Antiviral therapy of chronic hepatitis B: can we clear the ...<https://www.ncbi.nlm.nih.gov/pubmed/15646843>

Antiviral therapy of chronic HBV infection remains a clinical challenge. Once this infection has been established, the viral genome persists for life, either as an integrated genome or as episomal covalently closed circular DNA (cccDNA).

Cited by: 73

Author: Fabien Zoulim


Search Tools

Turn off Hover Translation (关闭翻译)

22-Jul-2021 10:13AM

4539 words • 16 matches • 8 sources

FAQ

 iThenticate®

64582_Auto_Edited.docx

Quotations Excluded
Bibliography Excluded

8%
similarity

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 64582

Manuscript Type: MINIREVIEWS

Challenges in the discontinuation of chronic hepatitis B antiviral agent

Challenges in NA discontinuation in CHB

Apichat Kaewdech, Pimsiri Sripongpun

Match Overview

1

Crossref 231 words
Apichat Kaewdech, Pim Tangjavanich, Pimsiri Sripongpun, Teepawat Witeerungrot et al. "Hepatitis B Surface Antigen, C

5%

2

Crossref 45 words
Apichat Kaewdech, Pim Tangjavanich, Pimsiri Sripongpun, Teepawat Witeerungrot et al. "Hepatitis B surface antigen, ...

1%

3

Internet 19 words
crawled on 11-Apr-2019
[onlineLibrary.wiley.com](#)

<1%

4

Crossref 18 words
Suzette Grace R. Kho-Herman, Henry Lik-Yuen Chan. "Si ...
pping nucleos(t)ide analog treatment in chronic hepatitis B

<1%

5

Internet 13 words
crawled on 12-Nov-2020
[www.wjnet.com](#)

<1%

6

Crossref 12 words
Pao-Yuan Huang, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chen-Chen Hung. "The role of

<1%

7

Crossref 12 words
Yuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chen-Chen Hung. "Combining e

<1%

8

Internet 12 words
crawled on 10-Jan-2020

<1%

PDF: 1 OF 15

Text-Only Report

国内版

国际版

Challenges in the discontinuation of chronic hepatitis B antiviral ag



ALL

IMAGES

VIDEOS

520,000 Results

Any time ▾

[Why not to stop antiviral treatment in patients with ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/29427480>

Why not to stop antiviral treatment in patients with chronic hepatitis B. Marciano S(1), Gadano A(1). Author information: (1)Liver Unit and Department of Research, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Treatment of chronic hepatitis B with entecavir or tenofovir leads to viral suppression in almost all patients.

Cited by: 8

Author: Sebastián Marciano, Adrián Gadano

Publish Year: 2018

[Antiviral therapy of chronic hepatitis B: can we clear the ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/15646643>

Antiviral therapy of chronic HBV infection remains a clinical challenge. Once this infection has been-established, the viral genome persists for life, either as an integrated genome or as episomal covalently closed circular DNA (cccDNA).

Cited by: 73

Author: Fabien Zoulim

Publish Year: 2004

[Outcome after discontinuing antiviral agents during ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/23273664>

However, there are limited data on the outcome in pregnant women after withdrawal of antiviral agents. OBJECTIVES: We aimed to investigate the outcome of stopping antiviral agents in pregnant women with chronic hepatitis B virus (HBV) infection. STUDY DESIGN: In this single-center, retrospective cohort study, 12 pregnant patients who had ...

Cited by: 23

Author: Hee Yeon Kim, Jong Young Choi, Chung-...

Publish Year: 2013

[Successful Withdrawal of Antiviral Treatment in Kidney ...](#)

<https://pubmed.ncbi.nlm.nih.gov/24628837>

Background: The optimal duration of antiviral therapy for kidney transplant recipients (KTR) with chronic hepatitis B virus (HBV) infection remains unclear. We reported the long-term outcomes after withdrawal of antiviral agent in KTR with chronic HBV infection. Methods: We retrospectively investigated the hepatitis B surface antigen (HBsAg)-positive KTR with antiviral agents between January ...

Cited by: 16

Author: J.-H. Cho, J.-H. Lim, G.-Y. Park, J.-S. Ki...